Chronic Myelomonocytic Leukemia Relapse After Transplant
Targeted Cancer Therapy Connect · 2025
DOI: 10.69709/ciconnect.2024.193713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Targeted Cancer Therapy Connect, 2025. Verfasst von Fakhra Alafeefi und 1 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Relapse of Chronic Myelomonocytic Leukemia after allogeneic hematopoietic stem cell transplantation remains a significant challenge, with relapse rates reaching up to 50%, contributing to poor survival outcomes. This paper explores the factors influencing relapse, including disease biology and persistence of residual disease. Current, post- transplant strategies, such as maintenance therapies and immunomodulatory treatments, are discussed for their potential to reduce the likelihood of relapse. It also highlights emerging therapies, such as CAR-T cell therapy, targeted therapies, epigenetic modulators, and innovative combinations being tested in clinical trials. The aim of the paper is to provide a comprehensive overview of existing and future approaches to improve patient outcomes by addressing relapse prevention in Chronic Myelomonocytic Leukemia following transplantation.
Zitieren
APA
Alafeefi, F., & Raza, A. (2025). Chronic Myelomonocytic Leukemia Relapse After Transplant. Targeted Cancer Therapy Connect. https://doi.org/10.69709/ciconnect.2024.193713
Vancouver
Alafeefi F, Raza A. Chronic Myelomonocytic Leukemia Relapse After Transplant. Targeted Cancer Therapy Connect. 2025. doi:10.69709/ciconnect.2024.193713
BibTeX
@article{Alafeefi2025,
author = {Alafeefi, Fakhra and Raza, Afsheen},
title = {Chronic Myelomonocytic Leukemia Relapse After Transplant},
journal = {Targeted Cancer Therapy Connect},
year = {2025},
doi = {10.69709/ciconnect.2024.193713}
}
EUVIMED